Free tool
FAERS Monitor: Pavblu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761298 or its brand name (Pavblu, Aflibercept-Ayyh). Reports on generic versions are filed under their own applications.
Reports
101
Serious
44
44% of reports
Hospitalization
4
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure9
- cough6
- endophthalmitis6
- eye pain6
- off label use6
- refusal of treatment by patient5
- device physical property issue4
- drug ineffective4
- headache4
- uveitis4
- blindness unilateral3
- cerebrovascular accident3
- death3
- diabetes mellitus3
- diarrhoea3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 40 |
| 2026 | 61 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,058 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endophthalmitisSignal | 6 | 208.5 | 95.9 | 1,039 |
| refusal of treatment by patientSignal | 5 | 159.6 | 67.9 | 637 |
| device physical property issueSignal | 4 | 108.8 | 41.6 | 326 |
| uveitisSignal | 4 | 61.4 | 23.5 | 181 |
| blindness unilateralSignal | 3 | 44.3 | 14.5 | 87 |
| treatment failureSignal | 9 | 22.6 | 12.1 | 166 |
| eye painSignal | 6 | 22.1 | 10.2 | 101 |
| diabetes mellitusSignal | 3 | 8.2 | 2.7 | 12 |
| coughSignal | 6 | 4.5 | 2.1 | 13 |
| cerebrovascular accident | 3 | 3.7 | 1.2 | 4 |
| off label use | 6 | 1.4 | 0.7 | 0 |
| headache | 4 | 1.3 | 0.5 | 0 |
| diarrhoea | 3 | 1.0 | 0.3 | 0 |
| death | 3 | 0.7 | 0.2 | 0 |
| drug ineffective | 4 | 0.6 | 0.2 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.